Get all premium features to the best stock analysis tool

Finranks

Finranks

Company

  • About us

Contact us

  • [email protected]

Follow us

  • Instagram
  • Telegram
  • LinkedIn

All rights reserved.

Privacy PolicyTerms of Conditions
  • Home
  • Markets
  • Screener
  • News
  • About
  1. Home
  3. TEM
T

Tempus AI, Inc. (TEM)

42.62

0.00 (0.00%)

  • Summary
  • News
  • Chart
  • Financial
  • Dividends
  • Forecast
  • Ownership
  • Profile
Tempus AI Reinforces Market Position With Collaborations in 2026
26.03.2026

Tempus AI Reinforces Market Position With Collaborations in 2026

TEM expands 2026 reach via strategic collaborations, boosting oncology, diagnostics and AI-driven insights to enhance care and drug development.

Tempus (TEM) Down 12.9% Since Last Earnings Report: Can It Rebound?
26.03.2026

Tempus (TEM) Down 12.9% Since Last Earnings Report: Can It Rebound?

Tempus (TEM) reported earnings 30 days ago. What's next for the stock?

Tempus AI's Diagnostics and Data Arms Drive Long-Term Growth Story
23.03.2026

Tempus AI's Diagnostics and Data Arms Drive Long-Term Growth Story

Tempus AI's dual-engine model drives $1.27B revenues, with Diagnostics dominating and Data monetization accelerating growth and pricing leverage.

Want $1 Million in Retirement? Invest $10,000 in These 2 AI Stocks and Hold for 10 Years.
21.03.2026

Want $1 Million in Retirement? Invest $10,000 in These 2 AI Stocks and Hold for 10 Years.

Recursion is using AI to develop new drug candidates much more efficiently than the overall industry. Tempus AI's $1.27 billion trailing revenue comes from a clinical data flywheel that no competitor can build from scratch.

Tempus and Blood Cancer United® Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries
17.03.2026

Tempus and Blood Cancer United® Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood Cancer United® (formerly The Leukemia & Lymphoma Society), the largest global nonprofit focused on blood cancer patient support, research, and advocacy, today announced a strategic collaboration to develop a comprehensive, patient-centered, real-world registry for pediatric acute myeloid leukemia (pAML), a rare and aggressive blood cancer. Part of.

Tempus AI Advances Clinical Applications and Healthcare Software
16.03.2026

Tempus AI Advances Clinical Applications and Healthcare Software

TEM expands its clinical software push with TIME trial-matching, Tempus Next care intelligence and an upgraded Tempus One AI assistant for providers.

Tempus AI Expands Clinical Validation of AI-Powered Cancer Diagnostics
12.03.2026

Tempus AI Expands Clinical Validation of AI-Powered Cancer Diagnostics

TEM advances precision oncology as studies validate IPS, PurIST and xF+ diagnostics, highlighting stronger guidance for cancer therapy and biomarker detection.

Videos

No Data

There is no data to display

Upgrades / Downgrades

TickerBrokerage FirmRatings ChangePrice TargetDate
TEMBTIG ResearchBuyundefined >> $60April 21st 2025
TEMJP MorganNeutral$50 >> $55February 25th 2025
TEMWilliam BlairMarket Performundefined >> undefinedFebruary 12th 2025

Press releases

Tempus and Blood Cancer United® Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries
17.03.2026

Tempus and Blood Cancer United® Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood Cancer United® (formerly The Leukemia & Lymphoma Society), the largest global nonprofit focused on blood cancer patient support, research, and advocacy, today announced a strategic collaboration to develop a comprehensive, patient-centered, real-world registry for pediatric acute myeloid leukemia (pAML), a rare and aggressive blood cancer. Part of.

Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings
11.03.2026

Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the publication of a new study in JCO Precision Oncology highlighting how advanced features of comprehensive genomic profiling (CGP) expand treatment options for cancer patients in community oncology settings. The study, conducted in collaboration with The Oncology Institute (TOI), reveals that features such as tumor-normal matched sequencing, R.

Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine
03.03.2026

Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Merck, known as MSD outside of the United States and Canada, today announced an expanded, multi-year collaboration aimed at accelerating the discovery and development of precision medicine biomarkers and supporting Merck's oncology and potentially broader therapeutic portfolios. “This collaboration builds on our existing relationship and reflects our shared.

Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference
26.02.2026

Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Morgan Stanley Technology, Media, and Telecom Conference on Tuesday, March 3 in San Francisco. Eric Lefkofsky, Tempus Founder and CEO, will participate in a fireside chat at 9:15 AM PST. The live webcast may be accessed directly using the following link: https://event.webcasts.com/starthere.jsp?ei=1753938&tp_k.